saracatinib

Action and Spectrum

Actions and Spectrum: 

Saracatinib is an investigational drug which has the inhibitory action on kinase enzyme it mainly targets on Src and Bcr-Abl tyrosine kinase. 

Drug Interaction

Adverse Reaction

Frequency not defined 

Fatigue 

Hematological toxicity 

Transaminitis 

Black Box Warning

Black box warning: 

None 

Contraindication / Caution

Contraindications/caution: 

None 

Pregnancy / Lactation

Pregnancy Warnings: 

Pregnancy category: N/A 

Lactation: 

Excretion of the drug into the human breast milk is unknown 

Pregnancy categories: 

Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester. 

Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women. 

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 

Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology: 

Saracatinib is a tyrosine kinase inhibitor which has anticancer properties and is helpful to treat ovarian carcinoma

Pharmacodynamics: 

Limited information is available

Pharmacokinetics: 

Limited information is available on ADME. 

Adminstartion

Administration: 

The route of administration is not fully known. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: saracatinib 

Why do we use saracatinib? 

Saracatinib is still under investigation which has anticancer properties showing high efficacy in treating solid tumors such as colorectal cancer and breast cancer.